STRIDES PHARMA SCI LTD
STAR · General/Diversified · NSE
₹1,049
Current Market Price
Fair Value (DCF)
₹1,370
Margin of Safety
+30.7%
Updated 1d ago
YieldIQ Score
78/100
Piotroski F-Score
8/9
Economic Moat
Wide
Confidence
45%
ROE
—
Debt/Equity
0.66
WACC
11.1%
Market Cap
₹9,666 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
20.1%
Return on capital employed
EV / EBITDA
13.5×
Enterprise multiple
Debt / EBITDA
2.2×
Leverage vs earnings
Interest Coverage
3.3×
EBIT covers interest
Current Ratio
1.20×
Short-term liquidity
Asset Turnover
0.73×
Revenue per ₹ of assets
Revenue CAGR (3Y)
13.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,048.65
Bear case
₹707.63
MoS -48.2%
Base case
₹1,370.19
MoS +23.5%
Bull case
₹1,603.27
MoS +34.6%
Ratio Trends
STAR · last 8 annual periods
ROE
138.9%
ROCE
19.9%
Operating Margin
—
Debt / Equity
0.73×
PE
15.9×
EV / EBITDA
22.7×
Historical Financials
STAR · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3316 Cr | ₹1979 Cr | ₹986 Cr | ₹618 Cr | ₹4392 Cr | +7.3% |
| EBITDA | — | ₹-274 Cr | ₹175 Cr | ₹344 Cr | ₹887 Cr | — |
| EBIT | ₹523 Cr | ₹131 Cr | ₹114 Cr | ₹99.5 Cr | — | -34.0% |
| PAT | ₹258 Cr | ₹201 Cr | ₹-13.8 Cr | ₹53.7 Cr | ₹3593 Cr | +93.2% |
| EPS (diluted) | ₹28.37 | ₹22.33 | ₹-1.06 | ₹5.83 | — | -32.7% |
| CFO | ₹481 Cr | ₹-283 Cr | ₹44.4 Cr | ₹-35.8 Cr | ₹684 Cr | +9.2% |
| CapEx | — | — | — | — | ₹-242 Cr | — |
| FCF | — | — | — | — | ₹442 Cr | +0.0% |
| Total Assets | — | ₹6976 Cr | ₹6638 Cr | ₹5838 Cr | ₹6049 Cr | -3.5% |
| Total Debt | — | — | ₹1635 Cr | ₹1397 Cr | ₹1880 Cr | +3.6% |
| Shareholders' Equity | — | — | ₹2212 Cr | ₹3561 Cr | ₹2586 Cr | +4.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
STAR vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| VIYASH VIYASH SCIENTIFIC LIMITED | -52.0% | 55 | Data Limited | 2.8% | — |
| AKUMS AKUMS | — | — | Pending | 11.0% | — |
| PGHL PROCTER & GAMBLE HEALTH L | -32.5% | 45 | Above Fair Value | 3.1% | — |
| SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
| SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for STAR in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. STRIDES PHARMA SCI LTD (STAR.NS) trades at 1048.65 vs a model fair value of 1370.19, a gap of 30.7%. Piotroski F-score: 8/9. Moat label: ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of STAR →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for STAR →
Compare
Head-to-head with peers
Compare STAR side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse STARNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.